Condition: Neuroendocrine Tumor of Pancreas (Disorder) · Neuroendocrine Tumor Grade 1 · Sponsor: Institut Paoli-Calmettes
Pancreatic radiofrequency ablation (RFA) could therefore be an alternative to the monitoring of pancreatic neuroendocrine tumors (PNETs) and more particularly nonfunctioning PNETs (NF-PNETs), which is costly and anxiety-inducing for patients. To date, only a few small studies have evaluated this treatment and the results are encouraging. It appears necessary to consider a large-scale study to ensure the efficacy and low morbidity of pancreatic RFA applied to PNETs.
This description comes directly from the study's public registry record.
Jihane PAKRADOUNI · +33491223778 · drci.up@ipc.unicancer.fr
Always discuss trial participation with your own doctor first.
| Institut Paoli Calmettes | Marseille, France | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04520932